Effects of melatonin in experimental stroke models in acute, sub-acute, and chronic stages

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 157-162

  Lin, Hsiao Wen ^a   Lee, E Jian ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Cerebral ischemia; Melatonin; Neuroprotection; Stroke

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALMODULIN; CASPASE 3; CYTOCHROME C OXIDASE; DOUBLECORTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MELATONIN; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROTEIN 14 3 3; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN ISCHEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SLEEP DISORDER; STROKE;

EID: 69949156813     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s4815     Document Type: Review

References (59)

1. Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood). 2005;230:104-117.
2. Cervantes M, Morali G, Letechipia-Vallejo G. Melatonin and ischemia-reperfusion injury of the brain. J Pineal Res. 2008;45:1-7.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
4. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
5. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79:1431-1568. (Pubitemid 29473320)
6. Warner DS, Sheng H, Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol. 2004;207:3221-3231.
7. Cheung RT, Tipoe GL, Tam S, Ma ES, Zou LY, Chan PS. Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res. 2006;41:337-343. (Pubitemid 44498219)
8. Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab. 2000;20:631-652.
9. Sadamoto Y, Igase K, Sakanaka M, et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun. 1998;253:26-32. (Pubitemid 29015594)
10. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A. 1998;95:4635-4640. (Pubitemid 28207965)
11. Siren AL, Ehrenreich H. Erythropoietin-a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci. 2001;251:179-184.
12. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001;413:527-531. (Pubitemid 32938751)
13. Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2008;153:252-262.
14. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys. 2001;34:237-256. (Pubitemid 33615836)
15. Reiter R, Tang L, Garcia JJ, et al. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 1997;60:2255-2271. (Pubitemid 27237237)
16. Tan DX, Manchester LC, Burkhardt S, et al. N1-acetyl-N2-formyl-5- methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J. 2001;15:2294-2296.
17. Ressmeyer AR, Mayo JC, Zelosko V, et al. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep. 2003;8:205-213. (Pubitemid 37236233)
18. Leon J, Escames G, Rodriguez MI, et al. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J Neurochem. 2006;98:2023-2033. (Pubitemid 44298263)
19. Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39:1751-1758.
20. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007;205:20-25.
21. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol. 2007;61:396-402. (Pubitemid 46878767)
22. Donnan GA. The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke. 2008;39:242.
23. Pei Z, Pang SF, Cheung RT. Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J Pineal Res. 2002;32:168-172. (Pubitemid 34309883)
24. Lee EJ, Wu TS, Lee MY, et al. Delayed treatment with melatonin enhances electrophysiological recovery following transient focal cerebral ischemia in rats. J Pineal Res. 2004;36:33-42. (Pubitemid 38130287)
25. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res. 2005;38:35-41. (Pubitemid 40139308)
26. Leon J, Macias M, Escames G, et al. Structure-related inhibition of calmodulin-dependent neuronal nitric-oxide synthase activity by melatonin and synthetic kynurenines. Mol Pharmacol. 2000;58:967-975. (Pubitemid 30800786)
27. Gilad E, Wong HR, Zingarelli B, et al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J. 1998;12:685-693. (Pubitemid 28247147)
28. Acuna-Castroviejo D, Martin M, Macias M, et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res. 2001;30:65-74.
29. Martin M, Macias M, Leon J, et al. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol. 2002;34:348-357. (Pubitemid 34164278)
30. Reiter RJ, Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res. 2003;58:10-19.
31. Sewerynek E, Reiter RJ, Melchiorri D, Ortiz GG, Lewinski A. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin. Hepatogastroenterology. 1996;43:898-905. (Pubitemid 26308371)
32. Okatani Y, Wakatsuki A, Reiter RJ, Enzan H, Miyahara Y. Protective effect of melatonin against mitochondrial injury induced by ischemia and reperfusion of rat liver. Eur J Pharmacol. 2003;469:145-152. (Pubitemid 36629560)
33. Sener G, Sehirli AO, Keyer-Uysal M, Arbak S, Ersoy Y, Yegen BC. The protective effect of melatonin on renal ischemia-reperfusion injury in the rat. J Pineal Res. 2002;32:120-126. (Pubitemid 34289590)
34. Manev H, Uz T, Kharlamov A, Joo JY. Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J. 1996;10:1546-1551. (Pubitemid 26384452)
35. Lee MY, Kuan YH, Chen HY, et al. Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats. J Pineal Res. 2007;42:297-309. (Pubitemid 46365068)
36. Li JH, Yu JP, Yu HG, et al. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005;2005:185-193.
37. Szczepanik M. Melatonin and its influence on immune system. J Physiol Pharmacol. 2007;58(Suppl 6):115-124.
38. Kilic E, Kilic U, Reiter RJ, Bassetti CL, Hermann DM. Tissue-plasminogen activator-induced ischemic brain injury is reversed by melatonin: role of iNOS and Akt. J Pineal Res. 2005;39:151-155. (Pubitemid 41140753)
39. Koh PO. Melatonin attenuates the focal cerebral ischemic injury by inhibiting the dissociation of pBad from 14-3-3. J Pineal Res. 2008;44:101-106.
40. Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TF. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J. 2004;18:869-871.
41. Das A, Belagodu A, Reiter RJ, Ray SK, Banik NL. Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J Pineal Res. 2008;45:117-124.
42. Watson BD, Prado R, Veloso A, Brunschwig JP, Dietrich WD. Cerebral blood flow restoration and reperfusion injury after ultraviolet laser-facilitated middle cerebral artery recanalization in rat thrombotic stroke. Stroke. 2002;33:428-434. (Pubitemid 34123382)
43. Wysokinski WE, Owen WG, Fass DN, Patrzalek DD, Murphy L, McBane RD 2nd. Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. J Thromb Haemost. 2004;2:1637-1644. (Pubitemid 40186182)
44. Marder VJ, Chute DJ, Starkman S, et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke. 2006;37:2086-2093. (Pubitemid 44309909)
45. Chen TY, Lee MY, Chen HY, et al. Melatonin attenuates the post-ischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice. J Pineal Res. 2006;40:242-250.
46. Cayli SR, Kocak A, Yilmaz U, et al. Effect of combined treatment with melatonin and methylprednisolone on neurological recovery after experimental spinal cord injury. Eur Spine J. 2004;13:724-732. (Pubitemid 40416840)
47. Letechipia-Vallejo G, Lopez-Loeza E, Espinoza-Gonzalez V, et al. Long-term morphological and functional evaluation of the neuroprotective effects of post-ischemic treatment with melatonin in rats. J Pineal Res. 2007;42:138-146. (Pubitemid 46233059)
48. Huerto-Delgadillo L, Anton-Tay F, Benitez-King G. Effects of melatonin on microtubule assembly depend on hormone concentration: role of melatonin as a calmodulin antagonist. J Pineal Res. 1994;17:55-62.
49. Benitez-King G, Hernandez ME, Tovar R, Ramirez G. Melatonin activates PKC-alpha but not PKC-epsilon in N1E-115 cells. Neurochem Int. 2001;39:95-102. (Pubitemid 32530634)
50. Rennie K, de Butte M, Frechette M, Pappas BA. Chronic and acute melatonin effects in gerbil global forebrain ischemia: long-term neural and behavioral outcome. J Pineal Res. 2008;44:149-156. (Pubitemid 351252917)
51. Moriya T, Horie N, Mitome M, Shinohara K. Melatonin influences the proliferative and differentiative activity of neural stem cells. J Pineal Res. 2007;42:411-418. (Pubitemid 46581666)
52. Kilic E, Kilic U, Bacigaluppi M, et al. Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice. J Pineal Res. 2008;45:142-148.
53. Hoehn BD, Palmer TD, Steinberg GK. Neurogenesis in rats after focal cerebral ischemia is enhanced by indomethacin. Stroke. 2005;36:2718-2724.
54. Toung TJ, Traystman RJ, Hurn PD. Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke. 1998;29:1666-1670. (Pubitemid 28365591)
55. Green PS, Yang SH, Nilsson KR, Kumar AS, Covey DF, Simpkins JW. The nonfeminizing enantiomer of 17beta-estradiol exerts protective effects in neuronal cultures and a rat model of cerebral ischemia. Endocrinology. 2001;142:400-406.
56. Weishaupt JH, Bartels C, Polking E, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res. 2006;41:313-323. (Pubitemid 44498217)
57. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003;70:334-341. (Pubitemid 37071318)
58. Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer's disease. Neuro Endocrinol Lett. 2002;23(Suppl 1):20-23.
59. Pei Z, Pang SF, Cheung RT. Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke. 2003;34:770-775. (Pubitemid 36307409)